In patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC) that progressed on EGFR-TKIs, ivonescimab combined with chemotherapy had demonstrated longer PFS compared to regimens such as chemotherapy plus amivantamab and lazertinib or chemotherapy plus immunotherapy and bevacizumab (23). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.